APA (7th ed.) Citation

Hsu, C., Yang, T., Hsu, C., Toh, H. C., Epstein, R. J., Hsiao, L., . . . Cheng, A. (2010). Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. British Journal of Cancer, 102(6), 981. https://doi.org/10.1038/sj.bjc.6605580

Chicago Style (17th ed.) Citation

Hsu, C.-H, et al. "Efficacy and Tolerability of Bevacizumab Plus Capecitabine as First-line Therapy in Patients with Advanced Hepatocellular Carcinoma." British Journal of Cancer 102, no. 6 (2010): 981. https://doi.org/10.1038/sj.bjc.6605580.

MLA (9th ed.) Citation

Hsu, C.-H, et al. "Efficacy and Tolerability of Bevacizumab Plus Capecitabine as First-line Therapy in Patients with Advanced Hepatocellular Carcinoma." British Journal of Cancer, vol. 102, no. 6, 2010, p. 981, https://doi.org/10.1038/sj.bjc.6605580.